Phase Ia trial of PSI 938 in patients with hepatitis C.
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2011
At a glance
- Drugs PSI 938 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms SAD
- Sponsors Pharmasset
- 07 Feb 2011 7- and 14-day results have been reported, according to a Pharmasset media release
- 28 Oct 2010 Results will be presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, according to a Pharmasset media release.
- 28 Jul 2010 Preliminary results have been announced by Pharmasset in a media release. Further results are expected in the third quarter of 2010.